NANOFÁRMACOS

Volver

Resultados 128 resultados LastUpdate Última actualización 08/12/2016 [21:49:00] pdf PDF




Solicitudes publicadas en los últimos 30 días / Applications published in the last 30 days



Página1 de 6 nextPage   Mostrar por página


NANOENCAPSULATION OF HYDROPHILIC ACTIVE COMPOUNDS

NºPublicación: EP3099293A1 07/12/2016

Solicitante:
YISSUM RES DEV COMPANY OF THE HEBREW UNIV OF JERUSALEM LTD [IL]

Resumen de: WO2015111062A1

The invention provides a nanoparticle comprising a water-soluble protein, a glucan and a hydrophilic active agent, the glucan being at least partially cross-linked by a metaphosphate.



traducir


 

DELIVERY OF NUCLEIC ACID-LIKE COMPOUNDS

NºPublicación: EP3100719A2 07/12/2016

Solicitante:
CALIFORNIA PACIFIC MEDICAL CENTER [US]

Resumen de: EP3100719A2

A process for preparing a microparticulate complex is provided. The process comprises (a) combining a particle-forming component ("PFC") and a nucleic acid-like component ("NAC") in a monophasic composition comprising water and a water-miscible, organic solvent to form a mixture wherein the PFC and the NAC are independently molecularly or micellarly soluble in the aqueous/organic solvent system, and (b) reducing the amount of the organic solvent in the mixture. This effects formation of the microparticulate complex of the NAC and the PFC. Also provided is a microparticulate complex that comprises a particle-forming component complexed to a nucleic acid-like component forming an approximately spherical particle, wherein the particle-forming component encloses an interior of the particle containing the nucleic acid-like component and the so-enclosed interior volume has less than about 50% (preferably less than 20%) of the volume containing free water. Also disclosed composition comprising water and particles of the microparticulate complex. According to the invention a nucleic acid-like component is delivered to a cell by (a) contacting the cell with a composition comprising water and the microparticulate complex, and (b) maintaining the contact for a time sufficient to allow the nucleic acid-based moiety to enter the cell. A therapeutic nucleic acid-like component is delivered into a patient in need thereof by administering a composition comprising water and particles of the m



traducir


 

TRANSMUCOSAL AND TRANSEPITHELIAL DRUG DELIVERY SYSTEM

NºPublicación: EP3099331A1 07/12/2016

Solicitante:
THE UNIV OF BIRMINGHAM [GB]

Resumen de: WO2015114324A1

The invention provides a transmembrane delivery system comprising: a pharmaceutically active moiety; and a polypeptide of up to 20 amino acids in length comprising a continuous region of at least 2, more typically at least 4 basic amino acids. Typically the system comprises a polypeptide which has the formula: (B)„ (A)m where B is a basic amino acid A is an acidic amino acid, and m and n and integers and n is at least 4 m is less than n.



traducir


 

TOPICAL DERMAL COMPOSITIONS

NºPublicación: EP3099291A1 07/12/2016

Solicitante:
ALLERGAN INC [US]

Resumen de: WO2015116711A1

The present invention provides topical dermal compositions useful for treating a variety of conditions associated with excess sebum production, such as for example acne.



traducir


 

LIQUID TOPICAL PHARMACEUTICAL NANO-EMULSION FORMULATIONS

NºPublicación: HK1216719A1 02/12/2016

Solicitante:
JRX BIOTECHNOLOGY INC [US]

Resumen de: WO2014106048A2

Aspects of the present invention are directed to compositions that are useful for delivery of an active ingredient to a subject. Some embodiments are formulated with an active ingredient, including, for example, a non-steroidal anti-inflammatory drug (NSAID), such as aspirin, ibuprofen, ketoprofen, or naproxen, acetaminophen, or a polypeptide or protein, such as insulin, wherein the active ingredient is stabilized and greater than 90% of the particles of the active ingredient have a particle size that is less than or equal to or any number in between 100, 90, 80, 70, 60, 50, 40, 30, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, or 4 nanometers, or smaller, as determined by Dynamic Light Scattering (DLS), using a volume -weighted particle size distribution calculation method.



traducir


 

PHOSPHOLIPID-COATED THERAPEUTIC AGENT NANOPARTICLES AND RELATED METHODS

NºPublicación: US2016346220A1 01/12/2016

Solicitante:
AUTOTELIC LLC [US]

Resumen de: US2016346220A1

Phospholipid-coated nanoparticles containing a therapeutic agent, compositions that include the nanoparticles, and methods for making and using the nanoparticles and compositions.



traducir


 

SULFOALKYL ETHER CYCLODEXTRIN COMPOSITIONS

NºPublicación: US2016346405A1 01/12/2016

Solicitante:
CYDEX PHARMACEUTICALS INC [US]

Resumen de: US2016346405A1

SAE-CD compositions are provided, along with methods of making and using the same. The SAE-CD compositions comprise a sulfoalkyl ether cyclodextrin having an absorption of less than 0.5 A.U. due to a drug-degrading agent, as determined by UV/vis spectrophotometry at a wavelength of 245 nm to 270 nm for an aqueous solution containing 300 mg of the SAE-CD composition per mL of solution in a cell having a 1 cm path length.



traducir


 

HOLLOW SILICA NANOSPHERES AND METHODS OF MAKING SAME

NºPublicación: US2016346404A1 01/12/2016

Solicitante:
THE REGENTS OF THE UNIV OF CALIFORNIA [US]

Resumen de: US2016346404A1

The disclosure provide hollow nanospheres and methods of making and using the same. The methods and compositions of the disclosure are useful for drug delivery and gene transfer.



traducir


 

MEANS AND METHODS FOR OCULAR DRUG DELIVERY

NºPublicación: US2016346203A1 01/12/2016

Solicitante:
UNIV GRONINGEN [NL]
EBERHARD- KARLS- UNIVERSIT\u00C4T T\u00DCBINGEN MEDIZINISCHE FAKULT\u00C4T [DE]

Resumen de: US2016346203A1

The invention relates to compositions and methods that utilize polymeric nanoparticles to deliver a therapeutic compound to ocular cells or ocular tissue. Provided is a drug-loaded micelle comprising self-assembled amphiphilic biopolymers, such as hydrophobically modified nucleic acids or polypeptides, for use as ophthalmic drug delivery system. Also provided are ophthalmic compositions and methods for preventing or treating an ophthalmic disease.



traducir


 

FORMATION OF CYCLOSPORIN A/CYCLODEXTRIN NANOPARTICLES

NºPublicación: US2016346347A1 01/12/2016

Solicitante:
OCULIS EHF [IS]

Resumen de: US2016346347A1

Methods of forming cyclosporin/cyclodextrin complex nanoparticles and microparticles, and administration of the nano- and microsuspension formed to an eye of a human or animal in the form of aqueous eye drops suitable to elicit or enhance tear formation and for treatment of diseases of the eye and surrounding areas. The aqueous eye drop composition contains cyclosporin and a mixture of α-cyclodextrin and γ-cyclodextrin as well as one or more stabilizing polymers. α-Cyclodextrin solubilizes cyclosporin while γ-cyclodextrin promotes formation of cyclosporin/cyclodextrin complex aggregates. The polymers stabilize the aqueous nano- and microsuspension.



traducir


 

Compositions and Methods for the Delivery of Therapeutics

NºPublicación: US2016346222A1 01/12/2016

Solicitante:
THE BOARD OF REGENTS OF THE UNIV OF NEBRASKA [US]

Resumen de: US2016346222A1

The present invention provides compositions and methods for the delivery of antivirals to a cell or subject.



traducir


 

BLOOD SUBSTITUTE COMPOSITION AND METHOD OF USE

NºPublicación: US2016346358A1 01/12/2016

Solicitante:
UNIV WASHINGTON [US]

Resumen de: US2016346358A1

The present disclosure provides oxygen-carrying nanoparticles, methods of making the nanoparticles, and methods of using the nanoparticles to carry oxygen in blood.



traducir


 

METHOD OF ENHANCING RADIATION THERAPY OF CANCER

NºPublicación: US2016346390A1 01/12/2016

Solicitante:
KOREA INST OF RADIOLOGICAL & MEDICAL SCIENCES [KR]

Resumen de: US2016346390A1

According to an aspect of the present disclosure, a method of enhancing neutron high linear-energy-transfer (LET) radiation therapy of cancer is provided, wherein the method includes administering an effective amount of gold nano-particles (GNPs) to a subject that needs neutron high LET radiation therapy of cancer, before or after radiation therapy.



traducir


 

PHOSPHOLIPID-COATED THERAPEUTIC AGENT NANOPARTICLES AND RELATED METHODS

NºPublicación: US2016346221A1 01/12/2016

Solicitante:
AUTOTELIC LLC [US]

Resumen de: US2016346221A1

Phospholipid-coated nanoparticles containing a therapeutic agent, compositions that include the nanoparticles, and methods for making and using the nanoparticles and compositions.



traducir


 

Methods for Superdisintegrant-Based Composite Particles for Dispersion and Dissolution of Active Pharmaceutical Agents

NºPublicación: US2016346209A1 01/12/2016

Solicitante:
NEW JERSEY INST OF TECH [US]

Resumen de: US2016346209A1

The present disclosure provides improved systems and methods utilizing colloidal/ultrafine superdisintegrant-based composite particles for dispersion and/or dissolution of active pharmaceutical agents. In general, the present disclosure utilizes a surfactant-free or near surfactant-free formulation by incorporating a wet milled SDI as a dispersant in the formulation. As such, the present disclosure provides for the preparation of surfactant-free or substantially surfactant-free formulations (e.g., nano-composite micro-particle formulations) by incorporating a wet-milled superdisintegrant (SDI) as the dispersant in the formulations. The advantageous SDI particles (e.g., colloidal/ultrafine SDI particles) of the present disclosure can be used to break-up the aggregates (e.g., nanoparticle aggregates) of the active agents (e.g. poorly water-soluble drugs) in the formulations (e.g., micro-particle formulations) and enhance the recovery of the nanoparticles of active agents during aqueous re-dispersion and their dissolution rate in vitro and in vivo.



traducir


 

SUSTAINED RELEASE FORMULATIONS USING NON-AQUEOUS CARRIERS

NºPublicación: US2016346357A1 01/12/2016

Solicitante:
AMYLIN PHARMACEUTICALS LLC [US]
ASTRAZENECA PHARMACEUTICALS LP [US]

Resumen de: US2016346357A1

The disclosure provides one-component, injectable, sustained release formulations which comprise microspheres containing active pharmaceutical ingredients (e.g., exenatide), wherein the microspheres are suspended in a non-aqueous carrier. The non-aqueous carrier can be an oil, a fractionated oil, triglycerides, diglycerides, monoglycerides, propylene glycol fatty acid diesters, and the like. The formulations offer distinct advantages of long shelf life for the stability and potency of the formulation and sustained release of active pharmaceutical ingredients to reduce the frequency of medication dosing and to increase patient compliance.



traducir


 

Synthetic Platelets

NºPublicación: US2016346327A1 01/12/2016

Solicitante:
THE REGENTS OF THE UNIV OF CALIFORNIA [US]

Resumen de: US2016346327A1

Provided herein are various functionalized particles comprising a shell, dendritic linkers, and functional moieties. The dendrimer linkers allow very large numbers of functional moieties to be bound to the shell. The functional moieties may comprise peptides which synergistically promote platelet aggregation and hemostasis in wounded tissues. The functionalized particles may further be effectors of wound healing, thrombolysis and other functions, depending on the selection of functional moiety. Functionalized polymers having these functions are provided as well.



traducir


 

NANOSUSPENSION OF NATURAL MATERIALS AND PREPARATION METHOD THEREOF

NºPublicación: US2016346201A1 01/12/2016

Solicitante:
BRAND WERNER [DE]
APURANO PHARMACEUTICALS GMBH [DE]

Resumen de: US2016346201A1

The present disclosure relates to a method for the preparation of a nanosuspension of at least one natural material, wherein the method comprises the steps of (a) providing at least one natural material having a particle size (D90) of less than 320 μm; (b) dispersing said at least one natural material of step (a) in a solvent; and (c) milling the dispersion of step (b) to a particle size (D90) of below 1000 nm. The nanosuspension is useful for the preparation of a medicament.



traducir


 

COMPOSITION FOR PREVENTING OR TREATING ISCHEMIC DISEASES, CONTAINING LIPOSOMES IN WHICH VEGF-DERIVED PEPTIDES ARE SUPPORTED

NºPublicación: WO2016190642A1 01/12/2016

Solicitante:
IND COOP FOUND CHONBUK NAT UNIV [KR]

Resumen de: WO2016190642A1

The present invention relates to: a pharmaceutical composition for preventing or treating ischemic diseases, containing liposomes in which vascular endothelial growth factor (VEGF)-derived peptides are supported; a method for treating ischemic diseases, comprising the step of administering the pharmaceutical composition to an individual suspected of having an ischemic disease; a use of the liposomes; and a kit for evaluating, using the liposomes, the amount of liposomes, in which VEGF-derived peptides are supported, delivered to ischemic lesions and of support materials released and absorbed. The composition, of the present invention, for preventing or treating ischemic diseases, containing liposomes in which VEGF-derived peptides are supported, the liposomes having an average particle size of 90 to 110 nm and a particle distribution of 50 to 200 nm and being surface-modified with polyethylene glycol, is capable of significantly increasing the absorption of VEGF compared with treatment using solely VEGF, thereby effectively treating ischemic diseases such as myocardial infarction, middle cerebral artery stenosis, lower limb ischemia, and cerebral infarction. In addition, the kit provided in the present invention can be useful in evaluating the amount of liposomes, in which VEGF-derived peptides are supported, delivered to ischemic lesions and of support materials released and absorbed, in a treatment step for a patient with ischemic diseases.



traducir


 

TARGETED LIPID PARTICLES FOR SYSTEMIC DELIVERY OF NUCLEIC ACID MOLECULES TO LEUKOCYTES

NºPublicación: WO2016189532A1 01/12/2016

Solicitante:
RAMOT AT TEL-AVIV UNIV LTD [IL]

Resumen de: WO2016189532A1

Disclosed are targeted lipid based particles for delivery of nucleic acid molecules (such as si RNA) to leukocytes (such as T-Cells and B-cells). Further disclosed are uses of the targeted lipid based particles for treating Leukocytes-associated diseases, such as, cancer.



traducir


 

Engineering synthetic brain penetrating gene vectors

NºPublicación: AU2015259362A1 01/12/2016

Solicitante:
THE JOHNS HOPKINS UNIV

Resumen de: AU2015259362A1

A synthetic gene delivery platform with a dense surface coating of hydrophilic and neutrally charged PEG, capable of rapid diffusion and widespread distribution in brain tissue, and highly effective gene delivery to target cells therein has been developed. Nanoparticles including nucleic acids, are formed of a blend of biocompatible hydrophilic cationic polymers and they hydrophilic cationic polymer conjugated to hydrophilic neutrally charged polymers such as polyethylene glycol. The nanoparticles are coated with polyethylene glycol at a density that imparts a near neutral charge and optimizes rapid diffusion through the brain parenchyma. Methods of treating a disease or disorder of the brain including administering a therapeutically effective amount of nanoparticles densely coated with polyethylene glycol are also provided.



traducir


 

ABUSE-RESISTANT DRUG FORMULATIONS WITH BUILT-IN OVERDOSE PROTECTION

NºPublicación: US2016346274A1 01/12/2016

Solicitante:
KASHIV PHARMA LLC [US]

Resumen de: US2016346274A1

Disclosed are solid oral pharmaceutical compositions that that are intended to provide protection against overdose and tampering, as well as abuse deterrence. The compositions contain a plurality of granules or multi-particulates. A first population of multi particulates contains an API or drug susceptible to abuse, a polymer matrix, and an outer coating that contains a cationic pH dependent polymer. These multi particulates also contain a plasticizer and a surfactant. A second population of multi particulates contains a viscosity building polymer and an alkaline buffering agent. Compositions may further include a disintegrant, and/or additional viscosity building polymers and/or alkaline buffering agents and/or ion exchange polymers. Also disclosed are the methods of making and using the compositions.



traducir


 

Topical formulations and uses thereof

NºPublicación: AU2015264181A1 01/12/2016

Solicitante:
OCULAR TECH SARL

Resumen de: AU2015264181A1

Provided herein include formulations for topical administration, such as ophthalmic formulations, and methods of using such formulations. In some aspects and embodiments the formulations may include a polyoxyl lipid or fatty acid, and or a polyalkoxylated alcohol and may include nanomicelles. Also include methods of treating or preventing diseases or conditions, such as ocular diseases or conditions.



traducir


 

Protein-based particles for drug delivery

NºPublicación: AU2015258891A1 01/12/2016

Solicitante:
DANA-FARBER CANCER INSTITUTE INC

Resumen de: AU2015258891A1

In one aspect, a method for forming particles is provided. The method may allow biocompatible particles comprising an agent (e.g., pharmaceutically active agent) to be produced absent one or more purification step (e.g., removal of excess reagent). In certain embodiments, particles, produced as described herein, can be utilized in a pharmaceutical composition and/or administered to a subject without further purification. The lack of one or more purification step may simplify manufacturing and/or minimize or eliminate the loss of agent from the particle after formation. In some embodiments, the method comprises associating albumin with an agent and crosslinking to form particles, such that little or no cytotoxic molecules are produced and/or remain after particle formation. Cross-linked albumin particles formed via the methods described herein may serve as biocompatible carriers for a variety of agents.



traducir


 

NANOPARTICLES FOR USE AS A THERAPEUTIC VACCINE

Nº publicación: WO2016189125A1 01/12/2016

Solicitante:
NANOBIOTIX [FR]

Resumen de: WO2016189125A1

The present invention relates to the field of human health and more particularly concerns nanoparticles for use as a therapeutic vaccine in the context of radiotherapy in a subject suffering of a cancer, in particular of a metastatic cancer or of a liquid cancer.


traducir



 

Página1 de 6 nextPage Mostrar por página

Volver